Thera-SAbDab

LIRILUMAB

>   Structural Summary
TherapeuticLirilumab
TargetKIRD2
Heavy ChainQVQLVQSGAEVKKPGSSVKVSCKASGGTFSFYAISWVRQAPGQGLEWMGGFIPIFGAANYAQKFQGRVTITADESTSTAYMELSSLRSDDTAVYYCARIPSGSYYYDYDMDVWGQGTTVTVSS
Light ChainEIVLTQSPVTLSLSPGERATLSCRASQSVSSYLAWYQQKPGQAPRLLIYDASNRATGIPARFSGSGSGTDFTLTISSLEPEDFAVYYCQQRSNWMYTFGQGTKLEIK
100% seqID Fv StructureNone
99% seqID Fv StructureNone
95-98% seqID Fv StructureNone
>   Metadata
FormatWhole mAb
IsotypeG4
Highest Clinical Trial (June '19)Phase-II
Estimated Status (June '19)Active
Recorded Developmental TechnologyMedarex UltiMAb Mouse
INN Year Proposed2012
INN Year Recommended2013
Companies InvolvedNovo Nordisk, Bristol-Myers Squibb, Dana-Farber Cancer Institute, Innate Pharma, National Cancer Institute (USA), Ono Pharmaceutical, PrECOG, University of Texas M. D. Anderson Cancer Center
Conditions Approvedna
Conditions ActiveChronic lymphocytic leukaemia, Head and neck cancer, Myelodysplastic syndromes, Solid tumours, Bladder cancer, Haematological malignancies, Multiple myeloma, Lymphoma
Conditions DiscontinuedAcute myeloid leukaemia, Hepatitis C
Notes

SAbDab paper: Dunbar, J., Krawczyk, K. et al (2014). Nucleic Acids Res. 42. D1140-D1146 [link]

Thera-SAbDab paper: Raybould, M.I.J., Marks, C. et al (2019). Nucleic Acids Res. gkz827 [link]